[go: up one dir, main page]

AU2003271681A1 - Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation - Google Patents

Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Info

Publication number
AU2003271681A1
AU2003271681A1 AU2003271681A AU2003271681A AU2003271681A1 AU 2003271681 A1 AU2003271681 A1 AU 2003271681A1 AU 2003271681 A AU2003271681 A AU 2003271681A AU 2003271681 A AU2003271681 A AU 2003271681A AU 2003271681 A1 AU2003271681 A1 AU 2003271681A1
Authority
AU
Australia
Prior art keywords
complement
methods
component
monoclonal antibody
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271681A
Other versions
AU2003271681A8 (en
Inventor
Marie-Ange Buysse
Hilde De Winter
Erik Hack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANQUIN BLOOD SUPPLY FOUNDATION AMSTERDAM
Stichting Sanquin Bloedvoorziening
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of AU2003271681A8 publication Critical patent/AU2003271681A8/en
Publication of AU2003271681A1 publication Critical patent/AU2003271681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003271681A 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation Abandoned AU2003271681A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02447190.6 2002-10-04
EP02447190 2002-10-04
US41894702P 2002-10-16 2002-10-16
US60/418,947 2002-10-16
PCT/EP2003/010989 WO2004031240A1 (en) 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Publications (2)

Publication Number Publication Date
AU2003271681A8 AU2003271681A8 (en) 2004-04-23
AU2003271681A1 true AU2003271681A1 (en) 2004-04-23

Family

ID=32071097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271681A Abandoned AU2003271681A1 (en) 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Country Status (2)

Country Link
AU (1) AU2003271681A1 (en)
WO (1) WO2004031240A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506629A (en) 2004-02-10 2007-05-02 Univ Colorado factor b inhibition, the alternative complement system pathway and related methods
CN101227924A (en) 2005-05-26 2008-07-23 科罗拉多大学评议会 Inhibition of the alternative complement pathway for the treatment of traumatic brain injury, spinal cord injury and related disorders
EP2236518B1 (en) 2007-03-14 2014-08-06 Alexion Cambridge Corporation Humaneered anti-factor B antibody
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev METHODS FOR STIMULATING LIVER REGENERATION
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody
EP3790897A1 (en) * 2018-04-03 2021-03-17 NGM Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
EP4291577A1 (en) * 2021-02-12 2023-12-20 Boehringer Ingelheim International GmbH Complement c3 antigen binding proteins
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2024086555A1 (en) 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies

Also Published As

Publication number Publication date
WO2004031240A1 (en) 2004-04-15
AU2003271681A8 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
WO2003083062A8 (en) Anti-il-tif antibodies and methods of using in inflammation
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
IL168058A0 (en) Antibodies that bind celi-associated ca 125/0722p and methods of use thereof
AU2003299778A1 (en) Antibodies against gpr64 and uses thereof
EP1609803A4 (en) Modified antibody against cd22 and utilization thereof
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2003241443A1 (en) Coating compositions with modified particles and methods of using the same
EP1581096A3 (en) Antigen pipa and antibodies that bind thereto
AU2002365228A1 (en) Antigen panels and methods of using the same
AU2003271681A1 (en) Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU2002366995A1 (en) My voice voice agent for use with voice portails and related products
AU2003219093A1 (en) Anti-hpv-16 e7 antibodies and their use
IL166063A0 (en) Antibodies and uses thereof
AU2003216367A1 (en) Biglycan and related therapeutics and methods of use
AU2003215244A1 (en) Complexes and methods of using same
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2003244237A1 (en) Monoclonal antibody against adiponectin, preparation method and use thereof
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2003249533A1 (en) Neoplasm specific antibodies and uses thereof
EP1633850A4 (en) Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase